Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | USP8 | P40818 | 2/20 | 0.35 |
| ▸ | USP7 | Q93009 | 2/20 | 0.35 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9448107 | 0.82 | HTT (0.41) | METAP1HTTCYP2A6USP8USP7 | |
| SCHEMBL1530494 | 0.78 | METAP1 (0.36) | METAP1SRD5A1SRD5A2S100A4CYP19A1 | |
| SCHEMBL29544 | 0.71 | METAP1 (0.39) | METAP1HTTSRD5A1SRD5A2HTR2A | |
| SCHEMBL6830270 | 0.67 | METAP1 (0.37) | METAP1HTTSRD5A1SRD5A2AHR | |
| SCHEMBL15282381 | 0.64 | SRD5A1 (0.64) | METAP1HTTSRD5A1SRD5A2HTR2A | |
| SCHEMBL29572171 | 0.64 | METAP1 (0.57) | METAP1HTTSRD5A1SRD5A2AHR | |
| SCHEMBL1922789 | 0.64 | METAP1 (0.57) | METAP1HTTSRD5A1SRD5A2AHR | |
| SCHEMBL10395493 | 0.63 | GPR84 (0.38) | CYP2A6USP8USP7USP47AHR | |
| SCHEMBL17272413 | 0.62 | CYP3A4 (0.35) | METAP1HTTSRD5A1SRD5A2AHR | |
| SCHEMBL17028333 | 0.62 | HTR2A (0.42) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589204-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589204-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589204-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | YOUNGMAN MICHAEL | 2009-07-23 | — | — | US | disclosed |
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | YOUNGMAN MICHAEL | 2009-07-23 | — | — | US | disclosed |
| US-7531661-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531661-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531661-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-20060047116-A1 | Indane compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-02 | — | — | US | disclosed |
| EP-1581530-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004055012-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047116-A1 | Indane compounds as ccr5 antagonists | CCR5, CCL5, IDO1 | METAP1 1596/4885HTT 4616/4885CYP2A6 2228/4885 |
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CCL5, IDO1 | METAP1 1596/4885HTT 4616/4885CYP2A6 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.